Improving Lives Through
Innovative Diagnostic Solutions
AXIM® Biotechnologies, Inc. (AXIM) is a vertically integrated research and development company focused on improving the landscape for the diagnosis of ophthalmological conditions such as Dry Eye Disease (DED) through rapid diagnostic tests.
Improving Lives Through
Innovative Diagnostic Solutions
AXIM® Biotechnologies, Inc. (AXIM) is a vertically integrated research and development company focused on improving the landscape for the diagnosis of ophthalmological conditions such as Dry Eye Disease (DED) through rapid diagnostic tests.
oncological
solutions
AXIM Biotech is in development of a rapid (10-minute) diagnostic test that detects active biomarkers for early detection of cancer
OPHTHALMOLOGICAL DIAGNOSTICS
AXIM has developed and commercialized two point-of-care ophthalmological diagnostic solutions focused on diagnosis of Dry Eye Disease (DED)
DIAGNOSTIC
TEST DEVELOPMENT
Through AXIM’s vertically integrated research and development platform, AXIM is capable of developing diagnostic solutions for a variety of conditions – based on the needs of the client
oncological
solutions
AXIM Biotech is in development of a rapid (10-minute) diagnostic test that detects active biomarkers for early detection of cancer
OPHTHALMOLOGICAL DIAGNOSTICS
AXIM has developed and commercialized two point-of-care ophthalmological diagnostic solutions focused on diagnosis of Dry Eye Disease (DED)
DIAGNOSTIC
TEST DEVELOPMENT
Through AXIM’s vertically integrated research and development platform, AXIM is capable of developing diagnostic solutions for a variety of conditions – based on the needs of the client
About AXIM
AXIM Biotechnologies (OTC: AXIM) is an international healthcare solutions company targeting ocular biomarkers. AXIM Eye is working with two highly specialized Point-of-Care (POC) lab testing solutions designed specifically to assist eye-care physicians in detecting and quantifying biomarkers associated with aqueous deficient dry eye disease and allergic conjunctivitis.
AXIM Biotechnologies, Inc. Announces Exclusive Distribution Agreement with VisionPlus Corp. for TearScan® Lactoferrin and IgE Diagnostic Tests in South Korea
San Diego, CA — October 23, 2025 — AXIM Biotechnologies, Inc. (“AXIM”), a leader in rapid, point-of-care ocular diagnostics, today announced it has entered into an exclusive distribution agreement with VisionPlus Corp. (“VisionPlus”) to market and distribute...
AXIM Biotechnologies Announces Exclusive Latin America License & Distribution Agreement With JK Medical for TearScan(R) Ocular Diagnostic Tests
Countries: Brazil, Chile, Peru, Argentina, Mexico, Ecuador, Colombia SAN DIEGO, CA - October 7, 2025 (NEWMEDIAWIRE) - AXIM Biotechnologies, Inc. (OTC: AXIM), a diagnostics company focused on rapid, point-of-care ophthalmic testing, today announced it has entered into...
Axim Biotechnologies Files Pre-Submission with FDA for CLIA Waiver Pathway on Lactoferrin Point-of-Care Diagnostic Test
San Diego, CA – June 24, 2025 – Axim Biotechnologies, Inc. (OTCQB: AXIM), a leading developer of rapid diagnostic testing for ocular and systemic conditions, today announced that it has filed a Pre-Submission (Pre-Sub Q) with the U.S. Food and Drug Administration...